Allos Therapeutics (ALTH) Presents Strong Data from PROPEL of FOLOTYN in Patients with Relapsed PTCL
Tweet Send to a Friend
Allos Therapeutics, Inc. (Nasdaq: ALTH) reported the following data from the PROPEL trial of FOLOTYN (pralatrexate injection) in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
